New York-based Constellation Brands has exercised warrants to purchase additional shares of Canopy Growth, increasing its stake in the Ontario cannabis producer.
Upon issuance, the common shares represented approximately 5% of Canopy’s issued and outstanding common shares, the companies said in a news release.
The transaction brings Constellation’s ownership in the Canadian firm to 38.6%.
At the time, it announced its intention to acquire 9.9% of the Smiths Falls company for 245 million Canadian dollars ($173 million).
The warrants were exercised at CA$12.98 per share.
Constellation has additional warrants and senior notes, that if converted and exercised, would increase its ownership further to approximately 55.8%.
“While global legalization of cannabis is still in its infancy, we continue to believe the long-term opportunity in this evolving market is substantial,” Constellation CEO Bill Newlands said in the release.
For the nine-month period ending Dec. 31, 2019, Canopy reported a net loss of 1.8 billion Canadian dollars ($1.3 billion).
The company’s new CEO made significant changes soon after taking over earlier this year.
“For a long time Canopy has prioritized doing things first, but going forward we’ll be focused on doing things the best in the markets and in the product formats that show the greatest promise,” Canopy CEO David Klein said in a statement to Marijuana Business Daily earlier this week.
Klein says he will share details of Canopy’s “new vision” following the company’s quarterly earnings call on May 29.
Canopy trades on the New York Stock Exchange as CGC and the Toronto Stock Exchange as WEED.
Pure Cannabis Hemp Oil
- Pure CBD Tincture, derived from organic, US-harvested hemp, lab-tested for quality.
- Clinically proven therapeutic effects.
- Relieves anxiety and stress
- Eliminates chronic pain and aches
- Regulates mood and sleep patterns
- Enhances focus and clarity
George Scorsis Aphria
Originally posted on via Cannabis Industry News
No comments:
Post a Comment